Gastroparesis: pharmacotherapy and cardiac risk

References

• Parkman HP, McCallum RW. Gastroparesis: pathophysiology, presentation, and treatment. New York (NY): Humana Press, 2012.
   Google Scholar
• Woosley RL, Romero KA. www.Crediblemeds.org, QTdrugs List, 15 April, 2017, AZCERT, Oro Valley, AZ, USA.
   Google Scholar
• De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol. 2001;57:185–209.
   PubMed Web of Science ®Google Scholar
• Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62:760–781.
   PubMed Web of Science ®Google Scholar
• Ponte M, Keller G, Girolamo G. Mechanisms of drug induced QT interval prolongation. Cds. 2010;5:44–53.
   Google Scholar
• Huang B-H, Wu C-H, Hsia C-P, et al. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol. 2007;30:1579–1582.
   PubMed Web of Science ®Google Scholar
• Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32–45.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol. 2001;96:1698–1703.
   PubMed Web of Science ®Google Scholar
• S7B, ICH Harmonised tripartite guideline, the non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. [Internet]. 2005. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf
   Google Scholar
• E14, ICH Harmonized Tripartite Guideline (2005). [Internet]. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf.
   Google Scholar
• Letsas KP, Efremidis M, Kounas SP, et al. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors. Clin Res Cardiol. 2009;98:208–212.
   PubMed Web of Science ®Google Scholar
• Yang KC, Foeger NC, Marionneau C, et al. Homeostatic regulation of electrical excitability in physiological cardiac hypertrophy. J Physiol. 2010;588:5015–5032.
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Pehlivanov N, Sugumar A, et al. Drug Insight: from disturbed motility to disordered movement–a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3:138–148.
   PubMedGoogle Scholar
• Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf. 2010;5:257–262.
   PubMedGoogle Scholar
• Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102:2036–2045.
   PubMed Web of Science ®Google Scholar
• The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) PRAC recommends restricting use of domperidone. 07 March 2014. [Internet]. EMA/129231/2014. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/03/news_detail_002039.jsp&mid=WC0b01ac058004d5c1.
   Google Scholar
• Claassen S, Zünkler BJ. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005;74:31–36.
   PubMed Web of Science ®Google Scholar
• Hondeghem LM. Domperidone: limited benefits with significant risk for sudden cardiac death. J Cardiovasc Pharmacol. 2013;61:218–225.
   PubMed Web of Science ®Google Scholar
• Biewenga J, Keung C, Solanki B, et al. Absence of QTc prolongation with domperidone: a randomized, double-blind, placebo- and positive-controlled Thorough QT/QTc Study in Healthy Volunteers. Clin Pharmacol Drug Dev. 2015;4:41–48.
   PubMed Web of Science ®Google Scholar
• Leelakanok N, Holcombe A, Schweizer ML. Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis. Clin Drug Investig. 2016;36:97–107.
   PubMed Web of Science ®Google Scholar
• Ehrenpreis ED, Roginsky G, Alexoff A, et al. Domperidone is commonly prescribed with QT-interacting drugs: Review of a community-based practice and a postmarketing adverse drug event reporting database. J Clin Gastroenterol. 2017;51:56–62.
   PubMed Web of Science ®Google Scholar
• van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33:1003–1014.
   PubMed Web of Science ®Google Scholar
• Health Canada, Summary Safety Review - DOMPERIDONE - Serious abnormal heart rhythms and sudden death (cardiac arrest), January 27, [Internet]. 2015. Available at http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/domperidone-eng.php
   Google Scholar
• U.S. Food & Drug Adminstration. Tegaserod maleate (marketed as Zelnorm) – Full Version [Internet]. 2013. Available at https://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm078972.htm
   Google Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35:745–767.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Nakamura E, Ohkura M, et al. Both 5-hydroxytryptamine 5-HT2A and 5-HT1B receptors are involved in the vasoconstrictor response to 5-HT in the human isolated internal thoracic artery. Clin Exp Pharmacol Physiol. 2008;35:836–840.
   PubMed Web of Science ®Google Scholar
• Beattie DT, Higgins DL, Ero MP, et al. An in vitro investigation of the cardiovascular effects of the 5-HT4 receptor selective agonists, velusetrag and TD-8954. Vasc Pharmacol. 2013;58:150–156.
   PubMed Web of Science ®Google Scholar
• Carbone F, Rotondo A, Andrews CN, et al. A controlled cross-over trial shows benefit of prucalopride for symptom control and gastric emptying enhancement in idiopathic gastroparesis. Gastroenterology. 2016;150:S213–S214.
   Web of Science ®Google Scholar
• Sanger GJ, Hellström PM, Näslund E. The hungry stomach: physiology, disease, and drug development opportunities. Front Pharmacol. 2010;1:145–160.
   PubMed Web of Science ®Google Scholar
• Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol. 2003;98:259–263.
   PubMed Web of Science ®Google Scholar
• Carbonell N, Pauwels A, Serfaty L, et al. Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am J Gastroenterol. 2006;101:1211–1215.
   PubMed Web of Science ®Google Scholar
• Katapadi K, Kostandy G, Katapadi M, et al. A review of erythromycin-induced malignant tachyarrhythmia-torsade de pointes. A case report. Angiology. 1997;48:821–826.
   PubMed Web of Science ®Google Scholar
• Stanat JC, Carlton CG, Crumb WJ Jr, et al. Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem. 2003;254:1–7.
   PubMed Web of Science ®Google Scholar
• Ray W, Murray K, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089–1096.
   PubMed Web of Science ®Google Scholar
• Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: point of interest. Clin Infect Dis. 2006;43:1603–1611.
   PubMed Web of Science ®Google Scholar
• Wayne AR, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881–1890.
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Westaway SM, Barnes AA, et al. GSK962040A: a small molecule, selective motilin receptor agonist, effective as stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil. 2009;21:657–664. e30-1.
   PubMed Web of Science ®Google Scholar
• Hellström PM, Tack J, Johnson LV, et al. The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. Br J Pharmacol. 2016;173:1768–1777.
   PubMed Web of Science ®Google Scholar
• Parthasarathy G, Ravi K, Camilleri M, et al. Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders. Neurogastroenterol Motil. 2015;27:1736–1746.
   PubMed Web of Science ®Google Scholar
• Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61:821–828.
   PubMed Web of Science ®Google Scholar
• Xiao G, Xie X, Fan J, et al. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis. Sci World J. 2014;2014:541950.
   Google Scholar
• Levin F, Edholm T, Schmidt PT, et al. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab. 2006;91:3296–3302.
   PubMed Web of Science ®Google Scholar
• Ejskjaer N, Vestergaard ET, Hellström PM, et al. Clinical trial: Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther. 2009;29:1179–1187.
   PubMed Web of Science ®Google Scholar
• Lembo A, Camilleri M, McCallum R, et al. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology. 2016;151:87–96.e6.
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–380.
   PubMed Web of Science ®Google Scholar
• Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (Probe 1). Pain Med. 2009;10:35–42.
   PubMed Web of Science ®Google Scholar
• Smith HS, Smith JM, Seidner P. Opioid-induced nausea and vomiting. Ann Palliat Med. 2012;1:121–129.
   PubMedGoogle Scholar
• Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387–2396.
   PubMed Web of Science ®Google Scholar
• Poulsen JL, Brock C, Olesen AE, et al. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol. 2014;7:345–358.
   PubMedGoogle Scholar
• Gottfridsson C, Carlson G, Lappalainen J, et al. Evaluation of the effect of naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers. Clin Ther. 2013;35:1876–1883.
   PubMed Web of Science ®Google Scholar
• Nisha A, Amit D, Viraj N, et al. Intravenous ondansetron causing severe bradycardia: Two cases. Ann Card Anaesth. 2009;12:170–1.
   Google Scholar
• http://www.ehealthme.com/ds/ondansetron/bradycardia/. 2017. Accessed on September 14, 2017.
   Google Scholar
• Goodin S. Cunningham R. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist. 2002;7:424–436.
   PubMed Web of Science ®Google Scholar
• Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003;37:1276–1286.
   PubMed Web of Science ®Google Scholar
• Freedman SB, Uleryk E, Rumantir M, et al. Ondansetron and the risk of cardiac arrhythmias: A systematic review and postmarketing analysis. Ann Emerg Med. 2014;64:19–25.e6.
   PubMed Web of Science ®Google Scholar
• Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA. 2013;310:2640–2649.
   PubMed Web of Science ®Google Scholar
• Ray WA, Meredith S, Thapa PB, et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004;75:234–241.
   PubMed Web of Science ®Google Scholar
• Chopra N, Laver D, Davies SS, et al. Amitriptyline activates cardiac ryanodine channels and causes spontaneous sarcoplasmic reticulum calcium release. Mol Pharmacol. 2009;75:183–195.
   PubMed Web of Science ®Google Scholar
• Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288.
   PubMed Web of Science ®Google Scholar